# RAGNAR (NCT04083976)

> A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04083976
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Advanced Solid Tumor
- Interventions: Erdafitinib
- Enrollment: 316
- Primary outcome: Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)
- Primary outcome: Core Panel Cohort: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 14
- Podcasts: 6
- YouTube: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ragnar-nct04083976

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04083976", "email": "<work email>"}; the inbox owner confirms by the emailed link.